AptarGroup, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ATR research report →
Range $135 – $160
Price Chart
About the company
AptarGroup, Inc. specializes in developing and manufacturing solutions for dispensing, sealing, and advanced material science, catering to a broad spectrum of industries such as beauty, personal care, home care, and the pharmaceutical sector (including prescription drugs, consumer health care, and injectables), alongside the food and beverage markets. Its operations are structured into three key segments: Pharma, Beauty + Home, and Food + Beverage.
- CEO
- Gael Touya
- IPO
- 1993
- Employees
- 14,000
- HQ
- Crystal Lake, IL, US
Get TickerSpark's AI analysis on ATR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $8.88B
- P/E
- 34.06
- Fwd P/E
- 25.25
- PEG
- -0.99
- P/S
- 2.25
- P/B
- 3.44
- EV/EBITDA
- 13.95
- Div Yield
- 1.37%
- Gross Margin
- 28.09%
- Op Margin
- 12.09%
- Net Margin
- 6.69%
- ROE
- 10.14%
- ROIC
- 8.45%
Latest fiscal year · YoY change
- Revenue
- $3.78B+5.4%
- Gross Profit
- $1.12B-17.6%
- Op Income
- $512.34M
- Net Income
- $392.79M+4.9%
- EPS
- $5.97+5.7%
- OCF Growth
- -11.4%
- FCF Growth
- -14.2%
- 52W High
- $148.63
- 52W Low
- $110.95
- 50D MA
- $129.42
- 200D MA
- $128.20
- Beta
- 0.32
- RSI (14)
- 58
- Avg Volume
- 474.96K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Aptar delivered 5% core sales growth with adjusted EPS at the high end of guidance, but profitability was mixed as Beauty North America and emergency-medicine mix continued to weigh on margins.· October 30, 2026
- Reported sales rose 6% to just over $1 billion; core sales grew 5% year over year across all three segments.
- Adjusted EPS was $1.52, down 6% versus $1.62 a year ago; adjusted EBITDA was $217 million and margin was 21.3%.
- Pharma core sales rose 1% overall, but 8% excluding the emergency-medicine headwind; management said the naloxone destocking will be behind them in Q4.
- Beauty core sales increased 8%, helped by prestige fragrance and color cosmetics, but North America margins remain the key problem.
- Closures posted 11% core sales growth, with management saying margin would have been within its long-term target range absent indexation pass-through pressure.
Reported sales increased 6% to just over $1 billion, and core sales increased 5% year over year. Adjusted EPS was $1.52, down 6% from $1.62 in the prior year period at comparable exchange rates. Gross margin declined 120 basis points year over year, adjusted EBITDA was $217 million, and adjusted EBITDA margin was 21.3% versus 23.2% a year ago. Segment core sales grew 1% in Pharma, 8% in Beauty, and 11% in Closures; Pharma was 8% ex-emergency medicine. The company recorded a combined $61.2 million pre-tax and $60.4 million after-tax charge, or $0.94 per diluted share, related to the Russian subsidiary deconsolidation, which was excluded from adjusted earnings. For Q4 2026, Aptar guided adjusted EPS to $1.39 to $1.47, and for full-year 2026 it kept capital investments at $260 million to $280 million and D&A at $310 million to $320 million.
Gael Touya said the quarter showed the underlying strength of Aptar’s businesses, with broad-based demand in Pharma, Beauty and Closures. He emphasized a focus on profitable growth, execution and disciplined capital allocation, while saying the company needs better profitability in Beauty North America and continued improvement in Closures and Pharma mix. He also spent significant time outlining the Pharma pipeline across ophthalmic, nasal, inhalation and injectables, framing the business as a long-term growth engine with breadth rather than reliance on one product or therapy.
Vanessa Kanu walked through the financials in detail, citing the 6% reported sales increase, 5% core sales growth, $217 million of adjusted EBITDA and 21.3% margin, plus adjusted EPS of $1.52. She said consolidated gross margin fell 120 basis points because of lower high-margin emergency-medicine sales and lower Beauty and Closures margins, while SG&A rose to $160 million from higher professional fees, an allowance for credit loss tied to Russian receivables and pension-related accounting effects. On cash, she highlighted year-to-date free cash flow of $198 million, cash from operations of $390 million, capex net of grants of $192 million, $272 million returned to shareholders, 1.3 million shares repurchased for $180 million, $204 million of cash and 1.49x leverage; she also noted a 4% dividend increase and $420 million remaining under repurchase authorization.
Analysts focused on Pharma margins, the emergency-medicine destock, and whether naloxone could return to a steadier GDP-plus growth rate after the inventory reset. Management said the $65 million negative impact from naloxone destocking is tracking as planned and will lapse in Q4, but that growth rates going forward will likely be lower than the prior exceptional period and visibility into the new baseline should improve by Q1 2027. Questions also probed Beauty North America, where Gael Touya said the company has diagnosed the issues and is working on execution and accountability, but that the turnaround will not be a quick fix. On Injectables and the Stevanato collaboration, management said the partnership is more about building the pipeline and improving customer decisions than immediate revenue contribution.
The call reinforced that Pharma remains a strong growth and margin platform, with 8% core sales growth ex-emergency medicine, a broad pipeline and management confidence that the naloxone headwind will be gone by Q4. Beauty showed solid top-line momentum, Closures was strong, and Aptar has room to improve profitability if it executes better in North America and captures more value from its premium technologies.
Margins were pressured by emergency-medicine mix, lower Beauty and Closures profitability, and especially persistent weakness in North America Beauty, which management said will take time to fix. The Russian subsidiary deconsolidation also created a sizable one-time charge, and management warned that naloxone’s post-destock growth rate will likely be lower than before, with limited visibility until early 2027.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.0%
- Shares Outstanding
- 63.39M
- Float Shares
- 62.78M
of shares held by institutions
565 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for ATR, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Michael T. McCaulHouse · TX10 | Buy | Jun 12, 26 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Jun 18, 26 | Filing → |
| Michael T. McCaulHouse · TX10 | Buy | Nov 19, 25 | Filing → |
| Michael T. McCaulHouse · TX10 | Buy | Sep 22, 25 | Filing → |
| Michael T. McCaulHouse · TX10 | Buy | Sep 11, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Jun 24, 25 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Aug 26, 24 | Filing → |
| Michael T. McCaulHouse · TX10 | Buy | Nov 1, 23 | Filing → |
| Michael T. McCaulHouse · TX10 | Buy | Nov 1, 23 | Filing → |
| Michael T. McCaulHouse · TX10 | Buy | Aug 8, 22 | Filing → |
| Michael T. McCaulHouse · TX10 | Buy | Aug 8, 22 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Feb 14, 22 | Filing → |
| Susie LeeHouse · NV03 | Sell | Sep 13, 19 | Filing → |
| Susie LeeHouse · NV03 | Sell | Sep 11, 19 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 6.92M | ▼ 42.89K |
| Blackrock, Inc. | 6.19M | ▲ 55.56K |
| State Farm Mutual Automobile Insurance Co | 4.74M | 0 |
| Vanguard Portfolio Management LLC | 3.63M | ▼ 13.59K |
| Morgan Stanley | 3.40M | ▼ 123.26K |
| Vanguard Capital Management LLC | 2.89M | ▼ 8.51K |
| Victory Capital Management Inc | 2.79M | ▲ 232.63K |
| State Street Corp | 2.76M | ▼ 103.96K |
| Dimensional Fund Advisors LP | 1.89M | ▲ 148.76K |
| Geode Capital Management, LLC | 1.73M | ▼ 13.64K |
| Neuberger Berman Group LLC | 1.48M | ▼ 66.42K |
| Fiduciary Management Inc | 1.43M | ▲ 8.64K |
Held by 552 ETFs
Biggest fund positions in ATR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 5, 26 | FOTIADES GEORGE L | other | 1,600 |
| Nov 2, 26 | Prieur Marc | sell | 2,000 |
| Sep 11, 26 | Ackerman Daniel | other | 0 |
| Feb 10, 18 | Ackerman Daniel | other | 0 |
| Mar 15, 24 | Ackerman Daniel | other | 0 |
| Mar 19, 27 | Ackerman Daniel | other | 0 |
| Mar 15, 25 | Ackerman Daniel | other | 0 |
| Mar 17, 26 | Ackerman Daniel | other | 0 |
| Sep 2, 26 | Vinczeller Shiela | sell | 765 |
| Sep 1, 26 | Touya Gael | other | 2,637 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ATR coverage
Recent articles, reports, and earnings notes.
No research on ATR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ATR report →Rakovina Therapeutics to Present ATR Inhibitor Data in PTEN-Deficient Prostate Cancer at the 38th EORTC-NCI-AACR Symposium
globenewswire.com · Nov 16
Atrium Therapeutics Reports Third Quarter 2026 Financial Results
prnewswire.com · Nov 12
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of AptarGroup, Inc. (NYSE: ATR)
prnewswire.com · Nov 10
Dividend Champion, Contender, And Challenger Highlights: Week of November 8
seekingalpha.com · Nov 6
Rakovina Therapeutics to Present Brain-Penetrant ATR Inhibitor Data at the 31st Society for Neuro-Oncology Annual Meeting
globenewswire.com · Nov 5
Dividend Announcements: October 24-30, 2026 (Part 1 Of 2)
seekingalpha.com · Nov 3
Investing in AptarGroup (ATR)? Don't Miss Assessing Its International Revenue Trends
zacks.com · Nov 2
Atrium Therapeutics to Present Nonclinical Data Showing ATR 1072 Reversed and Improved Features of PRKAG2 Syndrome During HCMS at AHA Scientific Sessions 2026
prnewswire.com · Nov 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.